AstraZeneca’s pipeline potential will offset expiry headwinds.
By Armando Uribe, Analytics Analyst
7 May 2016
During the 2015–25 forecast window, Datamonitor Healthcare forecast AstraZeneca’s prescription pharmaceutical sales to grow at a compound annual growth rate (CAGR) of 2.2% seeing a net increase in sales of $5.8bn. Sales growth generated from new launches will be sufficient to offset the dent in sales from expiry brands such as Crestor (rosuvastatin) and Nexium (esomeprazole).
AstraZeneca will look towards its oncology portfolio to be its main growth driver for the future. The oncology portfolio is expected to see the largest amount of growth out of all therapy areas largely attributed to durvalumab, a human monoclonal antibody targeting programmed death ligand 1 (PD-L1). AstraZeneca is testing durvalumab under an accelerated development program in which positive Phase II results would give it an opportunity to be amongst the first wave of PD-1 pathway-targeted drugs to reach the market.
Other growth drivers from AstraZeneca’s core therapeutic businesses, respiratory and diabetes, will expand the company’s launch portfolio. Datamonitor Healthcare forecasts that AstraZeneca’s respiratory business will be the second highest growth driver in terms of therapy area sales, growing at a CAGR of 3.1%. Launches of benralizumab and tralokinumab will help counter declines to Symbicort (budesonide/formoterol) and Pulmicort (budesonide). AstraZeneca’s diabetes products are expected to see an overall sales growth of $1,422m over the 2015–25 period, mainly attributed to a solid presence in all three sectors of the non-insulin antidiabetic market.
Datamonitor Healthcare’s company analysis on Pfizer explores global corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2015–25.
Get your free demo today – simply fill out the form to the right.